Wenjun Lan

Closest collaborators

The 15 strongest of 15 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

1. Patricia Santofimia‐Castaño · 3 shared papers, 2018–2019 · strength 0.28
   • Paper Dissecting the Anticancer Mechanism of Trifluoperazine on Pancreatic Ductal Adenocarcinoma. DOI 10.3390/cancers11121869↗
   • Paper Targeting the Stress-Induced Protein NUPR1 to Treat Pancreatic Adenocarcinoma. DOI 10.3390/cells8111453↗
   • Paper E2F signature is predictive for the pancreatic adenocarcinoma clinical outcome and sensitivity to E2F inhibitors, but n… DOI 10.1038/s41598-018-26613-z↗
2. Juan Iovanna · 3 shared papers, 2018–2019 · strength 0.28
   • Paper Dissecting the Anticancer Mechanism of Trifluoperazine on Pancreatic Ductal Adenocarcinoma. DOI 10.3390/cancers11121869↗
   • Paper Targeting the Stress-Induced Protein NUPR1 to Treat Pancreatic Adenocarcinoma. DOI 10.3390/cells8111453↗
   • Paper E2F signature is predictive for the pancreatic adenocarcinoma clinical outcome and sensitivity to E2F inhibitors, but n… DOI 10.1038/s41598-018-26613-z↗
3. Yi Xia · 2 shared papers, 2018–2019 · strength 0.16
   • Paper Targeting the Stress-Induced Protein NUPR1 to Treat Pancreatic Adenocarcinoma. DOI 10.3390/cells8111453↗
   • Paper E2F signature is predictive for the pancreatic adenocarcinoma clinical outcome and sensitivity to E2F inhibitors, but n… DOI 10.1038/s41598-018-26613-z↗
4. Ling Peng · 2 shared papers, 2018–2019 · strength 0.16
   • Paper Targeting the Stress-Induced Protein NUPR1 to Treat Pancreatic Adenocarcinoma. DOI 10.3390/cells8111453↗
   • Paper E2F signature is predictive for the pancreatic adenocarcinoma clinical outcome and sensitivity to E2F inhibitors, but n… DOI 10.1038/s41598-018-26613-z↗
5. Analía Meilerman Abuelafia · 1 shared paper, 2019 · strength 0.11
   • Paper Dissecting the Anticancer Mechanism of Trifluoperazine on Pancreatic Ductal Adenocarcinoma. DOI 10.3390/cancers11121869↗
6. Can Huang · 1 shared paper, 2019 · strength 0.11
   • Paper Dissecting the Anticancer Mechanism of Trifluoperazine on Pancreatic Ductal Adenocarcinoma. DOI 10.3390/cancers11121869↗
7. Nicolas Alejandro Fraunhoffer · 1 shared paper, 2019 · strength 0.11
   • Paper Dissecting the Anticancer Mechanism of Trifluoperazine on Pancreatic Ductal Adenocarcinoma. DOI 10.3390/cancers11121869↗
8. Olga Abián · 1 shared paper, 2019 · strength 0.09
   • Paper Targeting the Stress-Induced Protein NUPR1 to Treat Pancreatic Adenocarcinoma. DOI 10.3390/cells8111453↗
9. José L. Neira · 1 shared paper, 2019 · strength 0.09
   • Paper Targeting the Stress-Induced Protein NUPR1 to Treat Pancreatic Adenocarcinoma. DOI 10.3390/cells8111453↗
10. Philippe Soubeyran · 1 shared paper, 2019 · strength 0.09
    • Paper Targeting the Stress-Induced Protein NUPR1 to Treat Pancreatic Adenocarcinoma. DOI 10.3390/cells8111453↗
11. Raul A. Urrutia · 1 shared paper, 2019 · strength 0.09
    • Paper Targeting the Stress-Induced Protein NUPR1 to Treat Pancreatic Adenocarcinoma. DOI 10.3390/cells8111453↗
12. Gwen Alyce Lomberk · 1 shared paper, 2019 · strength 0.09
    • Paper Targeting the Stress-Induced Protein NUPR1 to Treat Pancreatic Adenocarcinoma. DOI 10.3390/cells8111453↗
13. Odile Gayet · 1 shared paper, 2018 · strength 0.08
    • Paper E2F signature is predictive for the pancreatic adenocarcinoma clinical outcome and sensitivity to E2F inhibitors, but n… DOI 10.1038/s41598-018-26613-z↗
14. Benjamin Bian · 1 shared paper, 2018 · strength 0.08
    • Paper E2F signature is predictive for the pancreatic adenocarcinoma clinical outcome and sensitivity to E2F inhibitors, but n… DOI 10.1038/s41598-018-26613-z↗
15. Nelson Dusetti · 1 shared paper, 2018 · strength 0.08
    • Paper E2F signature is predictive for the pancreatic adenocarcinoma clinical outcome and sensitivity to E2F inhibitors, but n… DOI 10.1038/s41598-018-26613-z↗

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.